skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: No-carrier-added (18F)-N-methylspiroperidol

Abstract

There is disclosed a radioligand labeled with a positron emitting radionuclide suitable for dynamic study in living humans with positron emission transaxial tomography. [.sup.18 F]-N-methylspiroperidol, exhibiting extremely high affinity for the dopamine receptors, provides enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to provide [.sup.18 F]-N-methylspiroperidol as a radioligand superior to known radioligands for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for this material is disclosed.

Inventors:
; ;
Issue Date:
Research Org.:
United States Of America, Department Of Energy
Sponsoring Org.:
USDOE
OSTI Identifier:
1176656
Patent Number(s):
H001209
Assignee:
United States Of America, Department Of Energy
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY

Citation Formats

Shiue, Chyng-Yann, Fowler, Joanna S., and Wolf, Alfred P. No-carrier-added (18F)-N-methylspiroperidol. United States: N. p., 1993. Web.
Shiue, Chyng-Yann, Fowler, Joanna S., & Wolf, Alfred P. No-carrier-added (18F)-N-methylspiroperidol. United States.
Shiue, Chyng-Yann, Fowler, Joanna S., and Wolf, Alfred P. Tue . "No-carrier-added (18F)-N-methylspiroperidol". United States. https://www.osti.gov/servlets/purl/1176656.
@article{osti_1176656,
title = {No-carrier-added (18F)-N-methylspiroperidol},
author = {Shiue, Chyng-Yann and Fowler, Joanna S. and Wolf, Alfred P.},
abstractNote = {There is disclosed a radioligand labeled with a positron emitting radionuclide suitable for dynamic study in living humans with positron emission transaxial tomography. [.sup.18 F]-N-methylspiroperidol, exhibiting extremely high affinity for the dopamine receptors, provides enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to provide [.sup.18 F]-N-methylspiroperidol as a radioligand superior to known radioligands for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for this material is disclosed.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {1993},
month = {7}
}

Patent:

Save / Share: